In addition, ChAT has been targeted for development of specific cholinergic biomarkers, for instance, for the development of positron emission tomography (PET) imaging probes to map early cholinergic changes in various cholinergic-related neurodegenerative diseases, including neuromotor disorders such as amyotrophic lateral sclerosis (ALS) and dementias such as AD [12,13]. Here, CHAT is linked to amyotrophic lateral sclerosis.